Latest News of MYGN
Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)
By Yahoo! Finance |
2 months ago
Myriad Genetics Inc focuses on molecular diagnostic testing for disease risk assessment and treatment guidance. Insider transactions reveal selling trend, with recent sale by Dale Muzzey. Stock priced...
Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN)
By Yahoo! Finance |
2 months ago
On September 11, 2024, Myriad Genetics Inc's CEO, Paul Diaz, sold 15,000 shares at $26.72 per share, owning 977,378 shares now. The company focuses on molecular diagnostic tests for disease risk asses...
Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN)
By Yahoo! Finance |
2 months ago
Myriad Genetics Inc specializes in predictive medicine tests assessing disease risk for personalized treatment. Recent insider sells, including Heinrich Dreismann's 10,000 shares, point to a trend wit...
-
Insider Sale at Myriad Genetics Inc (MYGN): SVP, Chief of Staff Margaret Ancona Sells Shares
By Yahoo! Finance | 2 months agoMargaret Ancona, Senior VP at Myriad Genetics Inc, sold 11,538 shares, now owning 79,366. Myriad Genetics specializes in genetic testing, aiding healthcare decisions. Ancona's sale reflects insider ac...
-
Insider Sale: Director Rashmi Kumar Sells 7,500 Shares of Myriad Genetics Inc (MYGN)
By Yahoo! Finance | 3 months agoMyriad Genetics Inc focuses on molecular diagnostics to improve patient care. Recent insider selling trends may indicate potential stock overvaluation. Investors monitoring insider behavior could cons...
-
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 30% Undervalued
By Yahoo! Finance | 5 months agoAn analyst's price target for MYGN is 27% lower than the fair value estimate. Using a 2-stage growth model and DCF analysis, the intrinsic value per share is calculated at US$3.1b, indicating a 30% di...